ha3ar

hA3AR agonist 2 is a potent activator of A3AR, with a Ki value of 3.5 nM.

hA3AR agonist 1 is a potent human A3 adenosine receptor (hA3AR) agonist with a Ki of 2.40 nM.

N6-Ethyladenosine, an adenosine derivative, acts as an agonist of Adenosine receptors (hA1AR and hA3AR) with Ki values of 4.9 nM and 4.7 nM, respectively.

MRS1177 is an effective and selective antagonist of the human Adenosine A3 receptor (hA3AR) (Ki: 0.3 nM).

MRS1186 is an effective and selective antagonist of the human Adenosine A3 receptor (Ki: 7.66 nM).

MRS1220, a selective and potent antagonist for the human A3 adenosine receptor (hA3AR) with a dissociation constant (Ki) of 0.59 nM, exhibits therapeutic promise for central nervous system disease research. It effectively diminishes glioblastoma tumor size and inhibits blood vessel formation in vivo.

hA2A hCA XII modulator 1 is a potent antagonist of the hA2A adenosine receptor (hA2AAR), a triazolopyrazine that acts on hA2AAR (Ki: 6.4 nM), hA1AR (Ki: 4.819 μM), and hA3AR (Ki>30 μM). hA2A hCA XII modulator 1 Also a potent inhibitor of human carbonic anhydrase XII (hCA XII), capable of acting on hCA XII (Ki: 6.2 nM), hCA II (Ki: 46 nM), hCA IX (Ki: 466 nM) and hCA I (Ki: 8.351 μM). hA2A hCA XII modulator 1 exhibits potential for cancer research.

Compound 23, designated as A2A A3 AR antagonist-1, is a dual fluorescent ligand targeting A2A and A3 adenosine receptors (AR), exhibiting dissociation constants (Ki) of 90 nM for hA2A AR and 31.8 nM for hA3 AR, respectively [1].

A3AR agonist 4, an A3 adenosine receptor (A3AR) agonist, exhibits an inhibitory affinity (K i) of 1.24 nM for hA3AR and dampens cAMP production with an EC 50 value of 0.17 nM. It is utilized in the study of inflammation and pain [1].

MRS8028 is an agonist for the A3 adenosine receptor (A3AR), binding with a Ki of 2.44 nM to hA3AR. The compound demonstrates potential in alleviating ischemic and inflammatory diseases.